Deals ramp up in Asia’s healthcare space with cancer focus

An acquisition in Hong Kong by the New Frontier Group, an IPO by Sunho Biologics on the HKEX and a $1.5bn investment into Singapore by AstraZeneca, are signs that investments in next generation cancer treatments are increasing in the region.
May 28, 2024

There have been several high profile deals and developments in Asia’s cancer treatment space over the last few weeks, showing the growing interest a range of investors have in the region's healthcare sector. 

This includes a $1.5 billion investment from UK-Swedish pharmaceutical giant AstraZeneca in Singapore, a listing on the Hong Kong Stock Exchange HKEX by Chinese biopharmaceutical firm Sunho Biologics and an acquisition in Hong Kong by the New Frontier Group of the Hong Kong Integrated Oncology Center, a leading private oncology medical platform. 

Garri Zmudze, general partner at venture capital firm LongeVC, told FinanceAsia on...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222